HCW Biologics annual return on equity
2021
2022
2023
2024
HCW Biologics Return on Equity (ROE) Growth & History (HCWB)
HCW Biologics's return on equity was −897.37% for fiscal 2024.
View full HCW Biologics company overviewHCW Biologics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −897.37% | −799.14 pp |
| 2023 | 2023-12-31 | −98.23% | −64.60 pp |
| 2022 | 2022-12-31 | −33.63% | +40.99 pp |
| 2021 | 2021-12-31 | −74.62% | — |
HCW Biologics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −79.14% | — |
| Q1 2026 | 2026-03-31 | 81.44% | — |
| Q4 2025 | 2025-12-31 | 218.75% | — |
| Q2 2024 | 2024-06-30 | −1,252.05% | −1237.98 pp |
| Q1 2024 | 2024-03-31 | −67.27% | −52.79 pp |
| Q4 2023 | 2023-12-31 | −57.22% | −43.67 pp |
| Q3 2023 | 2023-09-30 | −18.83% | −10.01 pp |
| Q2 2023 | 2023-06-30 | −14.07% | −6.72 pp |
| Q1 2023 | 2023-03-31 | −14.48% | −10.39 pp |
| Q4 2022 | 2022-12-31 | −13.55% | −7.52 pp |
| Q3 2022 | 2022-09-30 | −8.82% | +17.79 pp |
| Q2 2022 | 2022-06-30 | −7.35% | — |
| Q1 2022 | 2022-03-31 | −4.09% | — |
| Q4 2021 | 2021-12-31 | −6.03% | — |
| Q3 2021 | 2021-09-30 | −26.61% | — |
HCW Biologics return on equity trends
Between the periods ended 2021-12-31 and 2024-12-31, HCW Biologics's return on equity decreased from −74.62% to −897.37%, a change of −822.75 percentage points. The latest reported quarter, Q2 2026, shows −79.14%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HCW Biologics source filings ↗